Teva EVP sells 12,827 shares after RSU vesting

Accepted by SEC EDGAR 08/05/2026 - 04:04 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Teva Pharmaceutical Industries executive Placid Jover, Executive Vice President and Chief Human Resources Officer, converted 12,827 restricted share units into the same number of ordinary shares on August 3, 2026, then sold all 12,827 shares, including shares to cover tax-withholding obligations, at a weighted average $34.8757 under a Rule 10b5-1 trading plan, leaving 25,657 restricted share units outstanding from his August 2024 grant.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Jover Placid

Role See "Remarks"

Sold 12,827 shs ($447K)

Approx. gross sale proceeds $447K

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units F2, F6, F1	12,827	$0.00	$0.00
Exercise	Ordinary Shares F1, F2	12,827	--	--
Sale	Ordinary Shares F1, F3, F4, F5	12,827	$34.8757	$447K

Holdings After Transaction: Restricted Share Units — 25,657 contracts (Direct); Ordinary Shares — 6,774 shares (Direct)

Footnotes (6)

1. F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. F2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
3. F3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
4. F4. Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.
5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.66 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
6. F6. Restricted share units were granted on August 1, 2024, with 12,827 vested on each of August 1, 2025 and August 1, 2026, 12,827 vesting on August 1, 2027, and 12,830 vesting on August 1, 2028.

Key Figures

RSUs converted: 12,827 units Shares sold: 12,827 shares Weighted average sale price: $34.8757 per share +3 more

6 metrics

RSUs converted 12,827 units Restricted share units converted to ordinary shares on August 3, 2026

Shares sold 12,827 shares Ordinary shares sold on August 3, 2026 following RSU vesting

Weighted average sale price $34.8757 per share Weighted average price for shares sold, with trades from $34.66 to $35.07

Remaining RSUs 25,657 units Restricted share units held after the August 3, 2026 conversion

Future vesting 2027 12,827 units Restricted share units scheduled to vest on August 1, 2027

Future vesting 2028 12,830 units Restricted share units scheduled to vest on August 1, 2028

Key Terms

Restricted Share Units, Rule 10b5-1 trading plan, weighted average price, American Depositary Shares

4 terms

Restricted Share Units financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Teva (TEVA) executive Placid Jover report?

He converted 12,827 restricted share units into 12,827 ordinary shares and immediately sold all of those shares. The transactions occurred on August 3, 2026 and were tied to the vesting of his August 1, 2024 RSU grant at Teva Pharmaceutical Industries.

How many Teva (TEVA) shares did Placid Jover sell and at what price?

Placid Jover sold 12,827 ordinary shares of Teva at a weighted average price of $34.8757 per share. According to the filing, individual trades occurred at prices ranging from $34.66 to $35.07, inclusive, in multiple transactions on August 3, 2026, as reported.

Were Placid Jover’s Teva (TEVA) share sales under a Rule 10b5-1 plan?

Yes. The sale of Teva (TEVA) shares was effected under a Rule 10b5-1 trading plan adopted by Placid Jover on November 10, 2025, providing for pre-arranged transactions executed without further discretionary trading decisions at the time of sale under that plan.

How many restricted share units does Placid Jover still hold at Teva (TEVA)?

Following these transactions, Placid Jover held 25,657 restricted share units at Teva Pharmaceutical Industries. These remaining RSUs come from his August 1, 2024 grant and are scheduled to vest in two future tranches on August 1, 2027 and August 1, 2028.

What is the vesting schedule of Placid Jover’s August 2024 RSU grant at Teva (TEVA)?

The August 1, 2024 RSU grant to Placid Jover at Teva vests in four annual installments: 12,827 units vested on August 1, 2025; 12,827 on August 1, 2026; 12,827 are scheduled for August 1, 2027; and 12,830 for August 1, 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jover Placid

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See "Remarks"

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	08/03/2026		M		12,827	A	(2)	19,601	D
Ordinary Shares(1)	08/03/2026		S(3)		12,827(4)	D	$34.8757(5)	6,774	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	08/03/2026		M			12,827	(6)	(6)	Ordinary Shares(1)	12,827	$0	25,657	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

4. Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.66 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. Restricted share units were granted on August 1, 2024, with 12,827 vested on each of August 1, 2025 and August 1, 2026, 12,827 vesting on August 1, 2027, and 12,830 vesting on August 1, 2028.

Remarks:

Executive Vice President, Chief Human Resources Officer.

	/s/ Dov Bergwerk as attorney-in-fact for Placid Jover	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)